Cabazitaxel Export Market Intelligence: India's 59 Suppliers Shipping to 49 Countries — TransData Nexus 2026

Q: Who are the top cabazitaxel exporters from India?

The top cabazitaxel exporters from India are: 1. INTAS PHARMACEUTICALS LIMITED — $3.5M (38.4% market share); 2. MSN LABORATORIES PRIVATE LIMITED — $1.6M (17.0% market share); 3. DR REDDY S LABORATORIES LIMITED — $524.0K (5.7% market share); 4. DR REDDYS LABORATORIES LIMITED — $523.6K (5.7% market share); 5. INTAS PHARMACEUTICALS LTD — $273.9K (3.0% market share). Together they account for 69.7% of India's total cabazitaxel export value.

Q: What is the total export value of cabazitaxel from India?

The total export value of cabazitaxel from India is $9.2M USD, recorded across 307 shipment transactions from 59 active exporters to 49 destination countries. The average shipment value is $30.1K.

Q: Which countries import cabazitaxel from India?

India exports cabazitaxel to 49 countries worldwide. The top importing countries are: RUSSIA (25.7% share, $2.4M), ITALY (14.8% share, $1.4M), NETHERLANDS (12.9% share, $1.2M), POLAND (11.4% share, $1.1M), MALTA (8.5% share, $788.4K). These five markets account for 73.4% of total export value.

Q: What is the HS code for cabazitaxel exports from India?

The primary HS code for cabazitaxel exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of cabazitaxel exports from India?

The average unit price for cabazitaxel exports from India is $123.65 USD per unit, with prices ranging from $0.08 to $2237.14 depending on formulation, packaging, and order volume. The total market is valued at $9.2M across 307 shipments.

Q: Which ports handle cabazitaxel exports from India?

The primary ports for cabazitaxel exports from India are SAHAR AIR (15.6% of shipments), SAHAR AIR CARGO ACC (INBOM4) (14.7% of shipments), AHEMDABAD AIR (12.1% of shipments), AHEMDABAD AIR ACC (INAMD4) (10.4% of shipments), HYDERABAD AIR (8.1% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of cabazitaxel?

India is one of the world's leading exporters of cabazitaxel due to its large base of 59 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports cabazitaxel to 49 countries, demonstrating 25% global market coverage.

Q: What certifications do Indian cabazitaxel exporters need?

Indian cabazitaxel exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import cabazitaxel from India?

There are 107 registered buyers importing cabazitaxel from India, spread across 49 countries. The repeat buyer rate is 47.7%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top cabazitaxel supplier from India?

INTAS PHARMACEUTICALS LIMITED is the leading cabazitaxel exporter from India with a market share of 38.4% and total export value of $3.5M across 108 shipments. The top 5 suppliers together control 69.7% of total export value.

Suresh Sormare

Cabazitaxel

India Pharmaceutical Trade Intelligence

$9.2M59 Suppliers49 CountriesHS 30049049

ExportsIndia → RUSSIA25.7%India → ITALY14.8%

ImportsCANADA → India$304.7K UNITED STATES → India$105.3K

#1 Supplier: INTAS PHARMACEUTICALS #1 Buyer: ACCORD HEALTHCARE

Cabazitaxel Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Cabazitaxel to the World

Between 2022 and 2026, India exported $9.2M worth of cabazitaxel across 307 verified shipments to 49 countries — covering 25% of world markets in the Advanced Oncology segment. The largest destination is RUSSIA (25.7%). INTAS PHARMACEUTICALS LIMITED leads with a 38.4% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Cabazitaxel export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Cabazitaxel export data snapshot — $9.2M · 59 exporters · 49 countriesTransData Nexus · Indian Customs Data

Top Cabazitaxel Exporters from India

59 active exporters · Ranked by export value

View all 59 →

Top Cabazitaxel Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	INTAS PHARMACEUTICALS LIMITED	$3.5M	108	9	38.4%
2	MSN LABORATORIES PRIVATE LIMITED

Top Countries Importing Cabazitaxel from India

49 destination markets · Ranked by import value

All 49 countries →

Top Countries Importing Cabazitaxel from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	RUSSIA	$2.4M	25.7%
2	ITALY	$1.4M	14.8%
3	NETHERLANDS	$1.2M	12.9%
4	POLAND	$1.1M	11.4%
5	MALTA	$788.4K	8.5%
6	UNITED KINGDOM	$586.0K	6.4%
7	SPAIN	$543.8K	5.9%
8	CHILE	$439.6K	4.8%
9	SOUTH AFRICA	$225.2K	2.4%
10	ALGERIA	$203.3K	2.2%

RUSSIA is India's largest cabazitaxel export destination, absorbing 25.7% of total exports worth $2.4M. The top 5 importing countries — RUSSIA, ITALY, NETHERLANDS, POLAND, MALTA — together account for 73.4% of India's total cabazitaxel export value. The remaining 44 destination countries collectively receive the other 26.6%, indicating a focused distribution strategy targeting key markets.

Who Supplies Cabazitaxel to India?

3 origin countries · Total import value: $459.4K

India imports cabazitaxel from 3 countries with a combined import value of $459.4K. The largest supplier is CANADA ($304.7K, 3 shipments), followed by UNITED STATES and GERMANY. All values are from Indian Customs (DGFT) import records.

Countries Supplying Cabazitaxel to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	CANADA	$304.7K	3	66.3%
2	UNITED STATES	$105.3K	2	22.9%
3	GERMANY	$49.4K	2	10.7%

CANADA is the largest supplier of cabazitaxel to India, accounting for 66.3% of total import value. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Cabazitaxel

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, cabazitaxel is approved for the treatment of metastatic castration-resistant prostate cancer. The FDA's Orange Book lists several approved Abbreviated New Drug Applications (ANDAs) for cabazitaxel injection. Notably, on July 20, 2018, Breckenridge Pharmaceutical, Inc. received tentative approval for their ANDA 207619, with final approval granted on October 27, 2022. This approval indicates that the generic formulation is bioequivalent and therapeutically equivalent to the reference listed drug, Jevtana Injection, 60 mg/1.5 mL (40 mg/mL), by Sanofi-Aventis U.S. LLC. The presence of multiple ANDA approvals reflects a competitive market landscape, offering opportunities for Indian exporters to supply active pharmaceutical ingredients (APIs) or finished formulations to U.S. manufacturers.

2EU & UK Regulatory Framework

In the European Union, cabazitaxel is marketed under the brand name Jevtana, which received marketing authorization on March 17, 2011. Generic versions have also been approved; for instance, Cabazitaxel Accord was authorized on August 28, 2020. However, not all applications have been successful. On April 26, 2019, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion for Cabazitaxel Teva, recommending refusal of its marketing authorization. This decision underscores the stringent regulatory requirements in the EU, emphasizing the need for comprehensive clinical data and adherence to Good Manufacturing Practice (GMP) standards. For Indian exporters targeting the EU and UK markets, compliance with these regulations is imperative to ensure successful market entry.

3WHO Essential Medicines & Global Standards

Cabazitaxel is not currently listed on the WHO Model List of Essential Medicines. Consequently, it has not undergone the WHO Prequalification Programme, which primarily focuses on medicines for high-burden diseases. Nonetheless, cabazitaxel formulations must comply with international pharmacopoeial standards, including those set forth in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures product quality and facilitates acceptance in global markets.

4India Regulatory Classification

In India, cabazitaxel is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. As of March 2026, cabazitaxel is not listed under the Drug Price Control Order (DPCO) by the National Pharmaceutical Pricing Authority (NPPA), meaning it does not have a government-mandated ceiling price. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

5Patent & Exclusivity Status

Cabazitaxel's primary patents have expired, leading to increased generic competition. For example, U.S. Patent Number 7,241,907 expired on June 10, 2026, and U.S. Patent Number 8,927,592 is set to expire on April 27, 2031. The expiration of these patents has opened the market to generic formulations, intensifying competition among manufacturers and potentially impacting pricing strategies.

6Recent Industry Developments

In October 2022, the FDA approved Breckenridge Pharmaceutical's generic cabazitaxel injection, enhancing market competition and potentially reducing treatment costs. In April 2023, the EMA updated the product information for Jevtana to include new safety data, emphasizing the importance of ongoing pharmacovigilance. In June 2023, the EMA's CHMP adopted a positive opinion for Cabometyx, recommending a new indication for neuroendocrine tumors, reflecting the dynamic nature of oncology drug approvals. In September 2023, the WHO updated its Model List of Essential Medicines, though cabazitaxel was not included, indicating ongoing evaluations of treatment priorities. In December 2023, the NPPA in India reviewed the pricing of various oncology drugs, though cabazitaxel remained outside the purview of price control, highlighting the agency's selective approach to drug pricing regulations.

These developments underscore the evolving regulatory and market landscape for cabazitaxel, necessitating continuous monitoring by stakeholders to navigate the complexities of global pharmaceutical trade.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Cabazitaxel

Retail & reference prices across 9 markets vs. India FOB export price of $123.65/unit

Global Price Benchmark for Cabazitaxel across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$10,000	USD	According to the FDA Orange Book, cabazitaxel is approved for use in the U.S.
United Kingdom	$5,850	GBP	As per the NHS Drug Tariff, cabazitaxel is listed for use in the UK.
Germany	$5,500	EUR	The European Medicines Agency (EMA) has approved cabazitaxel for use in Germany.
Australia	$4,900	AUD

Supply Chain Risk Assessment — Cabazitaxel

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Cabazitaxel, a semi-synthetic taxane derivative used in prostate cancer treatment, relies on complex synthesis processes involving Key Starting Materials (KSMs). India, a major producer of Active Pharmaceutical Ingredients (APIs), imports a significant portion of these KSMs from China. This dependency is particularly pronounced in the production of taxane-based APIs like cabazitaxel, where China's dominance in KSM supply creates a strategic chokepoint. According to a 2024 report by the U.S. Pharmacopeia, many APIs depend on sole-sourced KSMs from China, highlighting the vulnerability in the supply chain.

Recent disruptions have underscored this risk. For instance, in November 2024, India inaugurated two greenfield plants under the Production Linked Incentive (PLI) scheme to manufacture critical molecules like Penicillin G and 6-APA, aiming to reduce import dependence. However, these efforts primarily target antibiotics, leaving other sectors, including oncology drugs like cabazitaxel, still vulnerable to supply chain disruptions stemming from China's control over KSMs.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of cabazitaxel account for 69.7% of total exports, with INTAS PHARMACEUTICALS LIMITED alone contributing 38.4%. This high supplier concentration poses a significant single-source risk. While the PLI scheme has incentivized domestic production of certain APIs and KSMs, its focus has been more on antibiotics and less on complex oncology drugs like cabazitaxel. Consequently, the cabazitaxel supply chain remains susceptible to disruptions due to limited diversification among suppliers.

Access Complete Cabazitaxel Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 307 transactions across 49 markets.

Request Demo View Pricing

Frequently Asked Questions — Cabazitaxel Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top cabazitaxel exporters from India?

The leading cabazitaxel exporters from India are INTAS PHARMACEUTICALS LIMITED, MSN LABORATORIES PRIVATE LIMITED, DR REDDY S LABORATORIES LIMITED, and 8 others. INTAS PHARMACEUTICALS LIMITED leads with 38.4% market share ($3.5M). The top 5 suppliers together control 69.7% of total export value.

What is the total export value of cabazitaxel from India?

The total export value of cabazitaxel from India is $9.2M, recorded across 307 shipments from 59 active exporters to 49 countries. The average shipment value is $30.1K.

Which countries import cabazitaxel from India?

India exports cabazitaxel to 49 countries. The top importing countries are RUSSIA (25.7%), ITALY (14.8%), NETHERLANDS (12.9%), POLAND (11.4%), MALTA (8.5%), which together account for 73.4% of total export value.

What is the HS code for cabazitaxel exports from India?

The primary HS code for cabazitaxel exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Cabazitaxel

Cabazitaxel

Top Cabazitaxel Exporters from India

Top Countries Importing Cabazitaxel from India

Who Supplies Cabazitaxel to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Cabazitaxel

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Cabazitaxel

Supply Chain Risk Assessment — Cabazitaxel

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Cabazitaxel Trade Intelligence

Frequently Asked Questions — Cabazitaxel Exports from India

Who are the top cabazitaxel exporters from India?

What is the total export value of cabazitaxel from India?

Which countries import cabazitaxel from India?

What is the HS code for cabazitaxel exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of cabazitaxel exports from India?

Which ports handle cabazitaxel exports from India?

Why is India a leading exporter of cabazitaxel?

What certifications do Indian cabazitaxel exporters need?

How many buyers import cabazitaxel from India?

What is the market share of the top cabazitaxel exporter from India?

Analysis Methodology